Effect of Allopurinol Alone Versus Allopurinol Plus Tadalafil on Cavernosal Uric Acid in Patients with Vasculogenic Erectile Dysfunction: A Comparative Study

Cavernosal uric acid level before and after allopurinol alone versus allopurinol plus daily tadalafil 5mg treatment in Vasculogenic Erectile Dysfunction Patients: A Comparative Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202506591686874

Enrollment

Registered

2025-06-20

Start date

2023-03-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological and Genital Diseases

Interventions

Allopurinol

Allopurinol and Tadalafil

Healthy control group

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Males aged 35–65 ED = 6 months IIEF-5 score = 21 Normal hormonal profile Willingness to consent

Exclusion criteria

Exclusion criteria: Recent cardiovascular event (<6 months) Severe hepatic/renal impairment On nitrate therapy Psychiatric drugs, antihypertensives, or recent ED treatments Peyronie’s disease

Design outcomes

Primary

Measure	Time frame
Change in cavernosal uric acid levels from baseline to 2 months and 4 months Change in IIEF-5 score	—

Secondary

Measure	Time frame
Penile duplex ultrasound parameters: PSV, EDV, RI Correlation between UA levels and IIEF-5 scores	—

Countries

Egypt

Contacts

Public ContactMohamed Hasan

Professor of Dermatology and Venereology

mohamed.saeed80@hotmail.com+201007212845

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026